dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Rho kinase (type: enzyme)
Target: Rho associated coiled-coil containing protein kinase 1

Ligand: belumosudil (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2021)
Primary target: yes
Median affinity: 4.619999885559082 pIC50
Reference (Journal): Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin.
Published in: Blood Coagul Fibrinolysis

Ligand: compound 22 [PMID: 20462760] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.409999847412109 pIC50
Reference (Journal): Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Published in: Bioorg Med Chem Lett

Ligand: compound 33 [PMID: 19364658] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.21999979019165 pIC50
Reference (Journal): Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
Published in: Bioorg Med Chem

Ligand: compound 35 [PMID: 20684608] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.
Published in: J Med Chem

Ligand: compound 8 [PMID: 25898023] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors.
Published in: J Med Chem

Ligand: compound E22 [PMID: 31298542] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.190000057220459 pIC50
Reference (Journal): Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design.
Published in: J Med Chem

Ligand: cortistatin A (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.599999904632568 pKd
Reference (Journal): Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11.
Published in: Angew Chem Int Ed Engl

Ligand: fasudil (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: 1995
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor.
Published in: Hypertension
Target family: Ribosomal factors (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum elongation factor 2

Ligand: M5717 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9 pEC50
Reference (Journal): A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Published in: Nature

Ligand: M5717 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.920000076293945 pEC50
Reference (Journal): A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Published in: Nature

Ligand: M5717 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.779999732971191 pEC50
Reference (Journal): A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Published in: Nature

Ligand: M5717 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.739999771118164 pEC50
Reference (Journal): A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Published in: Nature

Ligand: M5717 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8 pEC50
Reference (Journal): A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Published in: Nature

Ligand: M5717 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.739999771118164 pEC50
Reference (Journal): A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Published in: Nature
Target family: RIG-I-like receptor family (type: catalytic_receptor)
Target: DExD/H-box helicase 58

Ligand: SLR14 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice.
Published in: J Exp Med
Target family: RSK subfamily (type: enzyme)
Target: ribosomal protein S6 kinase A3

Ligand: FMK (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.820000171661377 pIC50
Reference (Journal): A clickable inhibitor reveals context-dependent autoactivation of p90 RSK.
Published in: Nat Chem Biol
Target family: RSK subfamily (type: enzyme)
Target: ribosomal protein S6 kinase A1

Ligand: BI-D1870 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.510000228881836 pIC50
Reference (Journal): BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.
Published in: Biochem J

Ligand: compound 33 [PMID: 19364658] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.539999961853027 pIC50
Reference (Journal): Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
Published in: Bioorg Med Chem

Ligand: compound E22 [PMID: 31298542] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.880000114440918 pIC50
Reference (Journal): Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design.
Published in: J Med Chem

Ligand: dorsomorphin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.679999828338623 pIC50
Reference (Journal): The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity.
Published in: Bioorg Med Chem Lett

Ligand: GSK-1838705A (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.800000190734863 pIC50
Reference (Journal): GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers.
Published in: Mol Cancer Ther

Ligand: GSK429286A (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.110000133514404 pIC50
Reference (Journal): Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
Published in: J Med Chem

Ligand: prexasertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
Published in: Mol Cancer Ther
Target family: RSK subfamily (type: enzyme)
Target: ribosomal protein S6 kinase A2

Ligand: BI-D1870 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.739999771118164 pIC50
Reference (Journal): BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.
Published in: Biochem J

Ligand: compound 25b [PMID: 22564207] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Published in: J Med Chem
Target family: RSK subfamily (type: enzyme)
Target: ribosomal protein S6 kinase A3

Ligand: BI-D1870 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.619999885559082 pIC50
Reference (Journal): BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.
Published in: Biochem J

Ligand: BIX 02565 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.960000038146973 pIC50
Reference (Journal): Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.
Published in: Bioorg Med Chem Lett

Ligand: compound 25b [PMID: 22564207] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.889999866485596 pIC50
Reference (Journal): Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Published in: J Med Chem

Ligand: compound 8h [PMID: 22765894] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.
Published in: Bioorg Med Chem Lett
Target family: RSK subfamily (type: enzyme)
Target: ribosomal protein S6 kinase A6

Ligand: AT-9283 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Published in: J Med Chem

Ligand: BAY-985 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.559999942779541 pIC50
Reference (Journal): Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
Published in: J Med Chem

Ligand: BI-D1870 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.820000171661377 pIC50
Reference (Journal): BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.
Published in: Biochem J

Ligand: compound 25b [PMID: 22564207] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Published in: J Med Chem
Target family: RSTK functional heteromers (type: catalytic_receptor)
Target: Growth/differentiation factor receptors

Ligand: growth/differentiation factor-9 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: RSTK functional heteromers (type: catalytic_receptor)
Target: Transforming growth factor &beta; receptor

Ligand: TGFβ1 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: TGFβ2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: TGFβ3 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: RSTK functional heteromers (type: catalytic_receptor)
Target: Bone morphogenetic protein receptors

Ligand: BMP-4 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: BMP-5 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: BMP-6 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: BMP-7 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: RSTK functional heteromers (type: catalytic_receptor)
Target: Growth/differentiation factor receptors

Ligand: growth/differentiation factor-7 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: growth/differentiation factor-3 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: growth/differentiation factor-10 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: growth/differentiation factor-1 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: RSTK functional heteromers (type: catalytic_receptor)
Target: Bone morphogenetic protein receptors

Ligand: BMP-9 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: BMP-8B (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: BMP-8A (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: RSTK functional heteromers (type: catalytic_receptor)
Target: Activin receptors

Ligand: activin A (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: activin AB (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: activin B (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: inhibin A (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: RSTK functional heteromers (type: catalytic_receptor)
Target: Anti-M&uuml;llerian hormone receptors

Ligand: Müllerian inhibiting substance (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: RSTK functional heteromers (type: catalytic_receptor)
Target: Bone morphogenetic protein receptors

Ligand: BMP-10 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: BMP-2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Target family: Ryanodine receptors (RyR) (type: vgic)
Target: RyR2

Ligand: carvedilol (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1995)
Primary target: no
Median affinity: 4.800000190734863 pIC50
Reference (Journal): Novel carvedilol analogues that suppress store-overload-induced Ca2+ release.
Published in: J Med Chem

Ligand: Ca2+ (Inorganic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Mg2+ (Inorganic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: procaine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1972)
Median affinity:  -

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: ryanodine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: ryanodine (Natural product)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -

Ligand: suramin (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: VK-II-86 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.769999980926514 pIC50
Reference (Journal): Novel carvedilol analogues that suppress store-overload-induced Ca2+ release.
Published in: J Med Chem
Target family: Ryanodine receptors (RyR) (type: vgic)
Target: RyR3

Ligand: ATP (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -

Ligand: caffeine (Natural product)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (no history prior to 1999), EMA (2009)
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: ryanodine (Natural product)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Mg2+ (Inorganic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: dantrolene (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1974)
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Target family: Ryanodine receptors (RyR) (type: vgic)
Target: RyR1

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: dantrolene (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: yes
Median affinity:  -

Ligand: Mg2+ (Inorganic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: procaine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1972)
Median affinity:  -

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: ryanodine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: ryanodine (Natural product)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: suramin (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Median affinity:  -
Target family: Ryanodine receptors (RyR) (type: vgic)
Target: RyR2

Ligand: ATP (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -

Ligand: caffeine (Natural product)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (no history prior to 1999), EMA (2009)
Median affinity:  -
Target family: Ryanodine receptors (RyR) (type: vgic)
Target: RyR1

Ligand: ATP (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: caffeine (Natural product)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (no history prior to 1999), EMA (2009)
Primary target: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -
Target family: RZ family (type: other_protein)
Target: regulator of G-protein signaling 17

Ligand: compound IV [PMID: 29351497] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.510000228881836 pIC50
Reference (Journal): Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.
Published in: SLAS Discov

Ligand: compound I [PMID: 29351497] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.019999980926514 pIC50
Reference (Journal): Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.
Published in: SLAS Discov

Ligand: compound II [PMID: 29351497] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.71999979019165 pIC50
Reference (Journal): Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.
Published in: SLAS Discov

Ligand: compound III [PMID: 29351497] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.840000152587891 pIC50
Reference (Journal): Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.
Published in: SLAS Discov

Ligand: celastrol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.980000019073486 pIC50
Reference (Journal): Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
Published in: J Nat Prod
Target family: RZ family (type: other_protein)
Target: regulator of G-protein signaling 19

Ligand: CCG-50014 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.960000038146973 pIC50
Reference (Journal): Differential Protein Dynamics of Regulators of G-Protein Signaling: Role in Specificity of Small-Molecule Inhibitors.
Published in: J Am Chem Soc
Target family: RZ family (type: other_protein)
Target: regulator of G-protein signaling 17

Ligand: pseudochelerythrine (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.139999866485596 pIC50
Reference (Journal): Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
Published in: J Nat Prod

Ligand: irigenol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.329999923706055 pIC50
Reference (Journal): Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
Published in: J Nat Prod

Ligand: compound V [PMID: 29351497] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.840000152587891 pIC50
Reference (Journal): Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.
Published in: SLAS Discov
Target family: S10: Carboxypeptidase Y (type: enzyme)
Target: Cathepsin A

Ligand: telaprevir (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Patent): Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases.

Ligand: example 166 [WO2014154727] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.039999961853027 pIC50
Reference (Patent): Biaryl-propionic acid derivatives and their use as pharmaceuticals.

Ligand: compound 8a [PMID: 22861813] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.420000076293945 pIC50
Reference (Journal): Novel β-amino acid derivatives as inhibitors of cathepsin A.
Published in: J Med Chem

Ligand: boceprevir (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2011)
Primary target: no
Median affinity: 6 pIC50
Reference (Patent): Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases.